Mielcarek and colleagues conducted a retrospective study of 221 patients who had matched related donors and 184 patients who had matched unrelated donors. All of the patients underwent mini transplants at the Hutchinson Center between December 1997 and June 2006. After adjusting for confounding factors such as comorbidities, relapse risk, patient age, stem-cell source, preparative regimen, and sex mismatch of donor and recipient, researchers found no statistically significant differences between patients who received unrelated and related matched donor cells in terms of rates of non-relapse mortality, relapse-related or overall mortality. Additionally, overall rates of severe acute and extensive chronic graft-versus-host disease between the two groups were not significantly different.
The preparative regimen for and the immunobiology of nonmyeloablative transplantation may account for the similar outcomes, according to the study. Patients who undergo mini transplants receive potent pre- and post-transplant immunosuppression drugs. This allows a major reduction in pre-transplant chemotherapy without compromising engraftment of the donor cells.
'/>"/>
| Contact: Dean Forbes dforbes@fhcrc.org 206-667-2896 Fred Hutchinson Cancer Research Center Source:Eurekalert |